ClinicalTrials.gg
Enrolling by invitationNCT05826379Updated Aug 12, 2026

Daily Goal Setting to Increase Everyday Physical Activity and Promote Cognitive Health in Midlife

An interventional study of Adaptive Daily Goal Setting and Interim Goal Prompt in Physical Inactivity, Walking and Cognitive Health, sponsored by Milton S. Hershey Medical Center. Enrolling by invitation at 1 site in United States. Open to participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether interaction with an adaptive Fitbit-based goal setting application can increase levels of everyday light intensity physical activity in middle-aged adults.

Read the detailed description

The study is designed to examine the efficacy of a Fitbit-based, goal setting, mHealth intervention to increase light intensity physical activity. The study design is a 2-arm randomized controlled trial. Both groups will receive the underlying goal-setting intervention (adaptive daily step goals). The study involves 3 phases: a run-in ("calibration") phase, the intervention ("training") phase, and follow-up (1- and 12-months post-intervention).

To support goal maintenance our team has developed a Fitbit application designed to operate on the Fitbit Versa series watch as a 'clockface'. The application will first calibrate participants' average level of physical activity by recording daily step counts for a period of 14 days (calibration phase). After this period (and following a health education session) the application will begin delivering the underlying intervention to both treatment and control groups for a period of 1 month. The intervention is composed of daily step goals presented via the Fitbit clockface. Each day the application will suggest a daily step goal. The algorithm used to make these suggestions relies on the participant's own activity during the calibration period and is updated each day in study, ensuring all proposed step goals are within their existing repertoire. Follow-up assessments will be completed at 1- and 12-monts post-intervention.

Outcomes and moderators will be measured via activity monitors (the Fitbit application and activPals), surveys, and ecological momentary assessments (self-ratings and performance-based ambulatory cognitive assessments) conducted via the Mobile Monitoring of Cognitive Change ("M2C2") platform.

Some of the details of the intervention, algorithm, experimental manipulations, and outcomes have been omitted to preserve the scientific integrity of the study. These details will be added after the study is closed.

02

Conditions studied

  • Physical Inactivity
  • Walking
  • Cognitive Health
  • Self-regulation
  • Overweight and Obesity
03

In context

Sedentary Behavior

1,273 studies on the registry are indexed under Sedentary Behavior; 300 are open to participants now.

This study's planned enrollment of 200 is above the median of 60 across 1,076 interventional studies indexed under Sedentary Behavior.

Browse Sedentary Behavior studies →

Lead sponsor

Milton S. Hershey Medical Center is the lead sponsor of 492 studies on the registry; 60 are open to participants now.

Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 30 and 70 years of age
  • ≥ 25

Exclusion criteria

Exclusion Criteria*:

  • Clinical diagnosis of ADRD or other neurodegenerative disease
  • Health condition for increased physical activity
  • Medical conditions or medications that would prohibit participation in an exercise test (e.g., decompensated heart failure, severe aortic stenosis, uncontrolled arrhythmia, and acute coronary syndromes)
  • Limitations in use of a smart phone (e.g., issues with manual dexterity or visual impairment)
  • Inability to walk unassisted
  • > 50
  • Plan to have surgery or other procedure over the next 12 months that could affect mobility or light intensity physical activity maintenance
  • Concurrent participation in a weight loss, physical activity, or cognitive training trial
  • Failure to comply with Run-in Period activity monitoring (\<70% valid wear days for the Fitbit and activPal)
  • Anyone who will not discontinue the use of their own personal smartwatch during the training period.
  • Anyone who scores below 19 on the -B would not be randomized after the Run-in Calibration Period.

Note: The eligibility criteria are deliberately incomplete to preserve the scientific integrity of the study. These details will be added after study closure.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Control

    Participants receive the adaptive daily step goal mHealth intervention

    Behavioral: Adaptive Daily Goal Setting

  • Experimental
    Treatment

    Participants receive the adaptive daily step goal mHealth intervention plus interim goal setting prompts each day

    Behavioral: Adaptive Daily Goal Setting · Behavioral: Interim Goal Prompt

Interventions

  • BehavioralAdaptive Daily Goal Setting

    Daily step goals displayed by the study application

  • BehavioralInterim Goal Prompt

    Short-term step goals

06

What researchers measure

Primary outcomes

  1. Short-term adherence

    Average of 14-day step count totals collected via ActivPal monitors

    Time frame: 1-month follow-up

  2. Long-term adherence

    Average of 14-day step count totals collected via ActivPal monitors

    Time frame: 12-month follow-up

Secondary outcomes

  1. Self-Monitoring Behavior

    Number of times participant checks their step count progress per day

    Time frame: Daily during intervention period

  2. Change in Cognitive Health (Processing Speed)

    Change in performance on ambulatory cognitive assessments of processing speed (response time during the "Symbol Search" task). This task is administered twice daily (2 "sessions" per day) throughout the 2-week, baseline "calibration phase" and twice daily throughout the 2-week, 12-month follow-up phase. The outcome to be modeled is median response time to trials administered during each session. Aggregation of data collected over these 2-week data collection periods will be model-based (in other words, all 'session' data will be modeled nested within phase, within persons).

    Time frame: Change in mean performance between the 2-week calibration phase and 12-month follow-up

  3. Change in Cognitive Health (Working Memory Binding)

    Change in performance on ambulatory cognitive assessments of working memory binding (corrected recognition rate during the "Color Shapes" task). This task is administered twice daily (2 "sessions" per day) throughout the 2-week, baseline "calibration phase" and twice daily throughout the 2-week, 12-month follow-up phase. The outcome to be modeled is corrected recognition rate (hit rate minus false alarm rate) for trials administered during each session. Aggregation of data collected over these 2-week data collection periods will be model-based (in other words, all 'session' data will be modeled nested within phase, within persons).

    Time frame: Change in mean performance between the 2-week calibration phase and 12-month follow-up

  4. Change in Self-Efficacy for light intensity physical activity

    Self-efficacy for exercise scale (adapted to light intensity physical activity; range 0-90 points; higher scores reflect better outcomes)

    Time frame: Change between pre-enrollment baseline survey and end of training phase (an average of 2 months)

  5. Executive Control (Working Memory Capacity)

    Performance on ambulatory cognitive assessments of working memory capacity (span score during the "Rotation Span" task). This task is administered twice daily (2 "sessions" per day) during the last 2 weeks of the "training phase". The outcome to be modeled is the total recalled arrows across the 3 trials assessed during each session. Data will not be aggregated, but instead modeled as a time-varying covariate.

    Time frame: Twice daily during the final 2 weeks of the training phase

  6. Executive Control (Inhibitory Control)

    Performance on ambulatory cognitive assessments of inhibitory control (commission errors during the "Go/NoGo" task). This task is administered twice daily (2 "sessions" per day) during the last 2 weeks of the "training phase". The outcome to be modeled is the total commission errors across the trials assessed during each session. Data will not be aggregated, but instead modeled as a time-varying covariate.

    Time frame: Twice daily during the final 2 weeks of the training phase

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for May 2027, 38 months after the start.

Of 733 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 38 months is above that.

Counting every sponsor, half of 741 studies reached it within 14 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2023
First posted
Apr 24, 2023
StartActual
Mar 20, 2024
Primary completionEst.
May 2027
CompletionEst.
Mar 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05826379
Responsible party
Christopher Sciamanna, MD, MPH (Professor, Medicine, Milton S. Hershey Medical Center) — Principal investigator
First posted
Apr 24, 2023
Start date
Mar 20, 2024
Primary completion
May 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Jonathan G Hakun, PhD
principal investigator · Milton S. Hershey Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion